{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T15:36:55Z","timestamp":1767973015892,"version":"3.49.0"},"reference-count":11,"publisher":"Elsevier BV","issue":"8-9","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.annder.2018.05.005","type":"journal-article","created":{"date-parts":[[2018,6,22]],"date-time":"2018-06-22T10:20:37Z","timestamp":1529662837000},"page":"556-558","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Risques de conjonctivite avec le dupilumab (Dupixent\u00ae)"],"prefix":"10.1016","volume":"145","author":[{"given":"J.-L.","family":"Schmutz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.annder.2018.05.005_bib0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2018.01.034","article-title":"Conjonctivitis occurring in atopic dermatitis patients treated with dupilumab-clinical characteristics and treatment","author":"Wollenberg","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.annder.2018.05.005_bib0065","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.intimp.2017.11.031","article-title":"Adverse events of Dupilumab in adults with moderate-to-severe atopic dermatitis: a meta-analysis","volume":"54","author":"Ou","year":"2018","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.annder.2018.05.005_bib0070","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1177\/1203475417743233","article-title":"Diagnostis and management of conjunctivitis for the dermatologist","volume":"22","author":"Gooderham","year":"2018","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.annder.2018.05.005_bib0075","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topicals corticosteroids (LIBERTY AD CHRONOS): a 1-year randomized double-blinded placebo-controlled phase 3\u00a0trial","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.annder.2018.05.005_bib0080","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jaad.2017.03.003","article-title":"Incidence prevalence and risk of selected ocular disease in adults with atopic dermatitis","volume":"77","author":"Thyssen","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2018.05.005_bib0085","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1136\/bjo.2009.173419","article-title":"Expression of the interleukin-4\u00a0receptor alpha in human conjunctival epithelial cells","volume":"94","author":"Ueta","year":"2010","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.annder.2018.05.005_bib0090","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s10384-011-0030-6","article-title":"Expression of interleukin-4\u00a0receptor \u03b1 in human corneal epithelial cells","volume":"55","author":"Ueta","year":"2011","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.annder.2018.05.005_bib0095","doi-asserted-by":"crossref","DOI":"10.1111\/bjd.16156","article-title":"Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFE)","author":"de Bruin-Weller","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2018.05.005_bib0100","doi-asserted-by":"crossref","DOI":"10.1111\/bjd.16330","article-title":"Could conjunctivitis in patients with atopic dermatitis treated with dupilumab be caused by colonization with Demodex and increased interleukin-17\u00a0levels?","author":"Thyssen","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2018.05.005_bib0105","doi-asserted-by":"crossref","DOI":"10.1111\/bjd.16348","article-title":"Could conjonctivitis in patients with atopic dermatitis treated with dupilumab be caused by colonization with Demodex and increased interleukin-17\u00a0levels?: reply from the authors","author":"de Bruin-Weller","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2018.05.005_bib0110","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ajoc.2017.06.017","article-title":"Cicatricial ectropion in a patient treated with dupilumab","volume":"7","author":"Barnes","year":"2017","journal-title":"Am J Ophthalmol Case Rep"}],"container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963818304435?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963818304435?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T11:06:24Z","timestamp":1758971184000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0151963818304435"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":11,"journal-issue":{"issue":"8-9","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S0151963818304435"],"URL":"https:\/\/doi.org\/10.1016\/j.annder.2018.05.005","relation":{},"ISSN":["0151-9638"],"issn-type":[{"value":"0151-9638","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risques de conjonctivite avec le dupilumab (Dupixent\u00ae)","name":"articletitle","label":"Article Title"},{"value":"Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annder.2018.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}